The ABCs of Assessing Cognition in Oncology Clinical Trials: Applications, Benefits, and Considerations
May 17, 2017
Featured Speaker Jeffrey S. Wefel, PhD, ABPP, Section Chief and Associate Professor, Section of Neuropsychology, Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center Nearly all patients with central nervous system (CNS) and many patients with non-CNS cancers experience cognitive problems during the course of their disease and treatment that can result in […]
Increasing the Precision of Cognitive Endpoints in Schizophrenia Clinical Trials
February 13, 2017
Featured Speaker: Paul Maruff – Chief Science Officer, Cogstate Cognitive impairment associated with schizophrenia (CIAS) is an important treatment target, and major unmet therapeutic need in the chronic stages of schizophrenia. Many studies have sought to ameliorate CIAS with new drugs but, as yet, no drug has been approved for treatment of CIAS. In acute […]
Optimizing CNS Endpoints Using Technology-enabled Workflows
November 16, 2016
The integrated rater experience: innovations in eLearning for rater training, eSource data capture and smarter central review Featured Speakers: Pamela Bynum – Learning & Operational Excellence Director, Cogstate Daniella Mulder – Senior Director of Project Management, Clinical Ink Lisle Kingery, PhD – Clinical Science Director, Cogstate A principal challenge in CNS clinical trials are the […]
The Preclinical Alzheimer Cognitive Composite: From Theory to Practical Application in Global Clinical Trials
September 6, 2016
Featured Speakers: Paul Maruff – Chief Science Officer Edward Bartolic – Senior Science Director Drug development strategies for early Alzheimer’s disease require clinical endpoints that are sensitive to the subtlest cognitive changes that may be occurring at even preclinical stages. The Alzheimer’s Disease Cooperative Study- Preclinical Alzheimer Cognitive Composite (ADCS-PACC), is based on retrospective analyses […]
